BioSpace News Archive

Transparency Market Research delivers key insights on the global medical loupes market.

Human erythropoietin is mostly produced by kidneys. It usually stimulates the human bone marrow to produce red blood cells.

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:15 a.m. EST.

Natus Medical Incorporated announced that Thomas J. Sullivan, President and Chief Executive Officer, and Drew Davies, Executive Vice President and Chief Financial Officer, will be presenting at the 24th Annual Needham Virtual Growth Conference from 2:00 PM to 2:40 PM ET on Friday, January 14th.

Sorrento Therapeutics, Inc. announced the unexpected passing of Mr. Najjam Asghar, Chief Financial Officer and Senior Vice President.

NRx Pharmaceuticals, a clinical-stage, biopharmaceutical company, announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be presenting updates to the Company’s business, including new details regarding late-stage trials of the investigational BriLife™ COVID-19 vaccine at the H.C. Wainwright BioConnect Virtual Conference.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will present data on Iovance tumor-infiltrating lymphocyte cell therapy at the upcoming Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, to be held February 2 – 6, 2022 in Salt Lake City, Utah, and virtually.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to nine new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Merck, known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2021 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 3. During the call, company executives will provide an overview of Merck’s performance for the quarter and outlook.

TCR2 Therapeutics Inc. announced that Garry Menzel, President and Chief Executive Officer of TCR2 Therapeutics, will present an update on Company progress at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30AM E.T. using a virtual platform.